Butyrylcholinesterase-injectable - Takeda
Alternative Names: BChELatest Information Update: 16 Jan 2019
At a glance
- Originator Shire Pharmaceutical Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cocaine-related disorders
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 26 Jul 2000 Butyrylcholinesterase is available for licensing (http://www.Shiregroup.com)
- 24 Jul 2000 Preclinical development for Cocaine abuse in USA (Injection)